EXEL - Exelixis, Inc.
22.15 -0.11 (-0.49%)
Pre-Market: 8:00AM EST
| Previous Close | 22.30 |
| Open | 22.34 |
| Bid | 21.85 x 1000 |
| Ask | 22.07 x 800 |
| Day's Range | 22.00 - 22.66 |
| 52 Week Range | 13.42 - 29.94 |
| Volume | 4,325 |
| Avg. Volume | 4,271,606 |
| Market Cap | 6.655B |
| Beta (3Y Monthly) | 2.21 |
| PE Ratio (TTM) | 10.07 |
| EPS (TTM) | 2.21 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.78 |
- Motley Fool•1 hour ago
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
A drug that disappointed in 2018 will get an unexpected dance at the big ball.
- Zacks•4 days ago
New Strong Sell Stocks for February 15th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•5 days ago
Implied Volatility Surging for Exelixis (EXEL) Stock Options
Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.
- CNBC•6 days ago
Cramer's lightning round: These are the two pot stocks I'm recommending
Jim Cramer rattles off his responses to callers' stock questions, including one on a top cannabis play.
- Motley Fool•6 days ago
Exelixis Grabs 90% of First Place
In a multibillion dollar cancer-treatment market, a solid second isn't too shabby.
- Zacks•6 days ago
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
- TheStreet.com•6 days ago
Exelixis Rises as Fourth-Quarter Earnings Beat Estimates
The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.
- TheStreet.com•6 days ago
These 'Small Ball' Names Will Outperform the Market in 2019
This is the last heavy week of fourth quarter reports from companies within the S&P 500, with some 60 names reporting during the week. Earnings growth has been better than expected to this point with year-over-year profit growth north of 16%. While not the 20%-plus we have seen over the past few quarters, it is solidly above the approximate 14% rise that was the consensus before fourth quarter results started to hit the wires.
- Benzinga•6 days ago
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of EXEL earnings conference call or presentation 12-Feb-19 10:00pm GMT
Q4 2018 Exelixis Inc Earnings Call
Motley Fool•6 days agoExelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript
EXEL earnings call for the period ending December 31, 2018.
- Associated Press•7 days ago
Exelixis: 4Q Earnings Snapshot
On a per-share basis, the Alameda, California-based company said it had profit of $1.15. Earnings, adjusted for pretax gains, came to 37 cents per share. The results beat Wall Street expectations. The ...
- Zacks•7 days ago
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 48.00% and 16.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•7 days ago
Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- Total Revenue of $228.6 million for the Fourth Quarter of 2018, $853.8 million for the Full Year 2018 -
- Business Wire•7 days ago
Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts
Exelixis, Inc. (EXEL) today announced it is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound to enter the clinic following the company’s reinitiation of drug discovery activities. The molecule is the subject of an active Investigational New Drug (IND) application Exelixis submitted to the U.S. Food and Drug Administration in December 2018. “Exelixis is building a pipeline of diverse investigational medicines behind cabozantinib through in-house drug discovery activities and targeted in-licensing,” said Peter Lamb, Ph.D., Executive Vice President of Scientific Strategy and Chief Scientific Officer of Exelixis.
- ACCESSWIRE•7 days ago
Exelixis, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 12, 2019 / Exelixis, Inc. (NASDAQ: EXEL ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 12, 2019 at 5:00 PM ...
- Benzinga•7 days ago
Q4 Earnings Preview For Exelixis
Exelixis (NASDAQ: EXEL ) releases its next round of earnings this Tuesday, Feb. 12. Here's Benzinga's essential guide to Exelixis's Q4 earnings report. Earnings and Revenue Exelixis EPS will likely be ...
- Benzinga•7 days ago
The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 11) Boston Scientific Corporation (NYSE: BSX ) Inspire ...
- Benzinga•9 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Biotech stocks held steady in the recent week as earnings from the sector continue to trickle in. The week also saw presentations of clinical trial readouts at a couple of conferences. The following are ...
- Markit•11 days ago
See what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXELView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EXEL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $4.07 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•12 days ago
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
- Business Wire•12 days ago
Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019
̶ Presentation to be webcast on www.exelixis.com ̶
- Simply Wall St.•13 days ago
Here’s What Exelixis, Inc.’s (NASDAQ:EXEL) P/E Ratio Is Telling Us
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! This article is for investors who would Read More...
- Zacks•14 days ago
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•18 days ago
Factors of Influence in 2019, Key Indicators and Opportunity within Exelixis, Varian Medical, DXC Technology, Bridgepoint Education, Armstrong World Industries, and Immunomedics — New Research Emphasizes Economic Growth
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
